AGS-003

BIOLOGICAL4 trials

Sponsors

Argos Therapeutics

Conditions

Advanced Renal Cell CarcinomaMetastatic Renal Cell CarcinomaRenal Cell Carcinoma

Phase 1

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

CompletedNCT00272649

Argos TherapeuticsRenal Cell Carcinoma

Start: 2006-01-31End: 2012-02-29Updated: 2013-03-14

Phase 2

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

CompletedNCT00678119

Argos TherapeuticsRenal Cell Carcinoma

Start: 2008-01-31End: 2012-05-31Updated: 2013-07-15

A Rollover Protocol for Subjects Previously Treated With AGS-003

TerminatedNCT01482949

Argos TherapeuticsRenal Cell Carcinoma

Start: 2011-09-30End: 2018-05-31Updated: 2018-06-27

Phase 3

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

TerminatedNCT01582672

Argos TherapeuticsAdvanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma

Start: 2012-11-30End: 2018-04-30Updated: 2018-06-14

Related Papers

Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

Journal of Clinical Oncology2018-05-201 citations

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Journal for ImmunoTherapy of Cancer2015-04-16210 citations

Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib.

Journal of Clinical Oncology2014-05-206 citations

ADAPT: An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC).

Journal of Clinical Oncology2014-02-0122 citations